The Johns Hopkins Hospital Completes Its First MUSE Procedure For The Long-Term Treatment of GERD


OMER, Israel, April 22, 2015 — Medigus Ltd. (TASE: MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, announced today that Dr. Mouen Khashab, Associate Professor of Medicine and Director of Therapeutic Endoscopy at The Johns Hopkins Hospital, an integrated global health enterprise and one of the leading health care systems in the United States, recently completed the first Medigus Ultrasonic Surgical Endostapler (MUSE) procedure at their facility. The MUSE system is used for an incisionless procedure for the treatment of gastroesophageal reflux disease (GERD) and is leading the transition to more patient-friendly procedures for the long-term treatment of this prevalent disorder.

Johns Hopkins has long been committed to innovative technologies to both enhance patient care and challenge convention of traditional medicine to deliver more effective treatments for widespread disorders, such as GERD. MUSE offers a unique new option for the millions of Americans who suffer from persistent GERD symptoms and who currently don’t have suitable therapies available to them. With the MUSE procedure, Dr. Khashab was able to reinforce the failing lower esophageal sphincter, thereby repairing the cause of the disorder without incisions. No incisions likely means greater comfort for patients, shorter hospital stays and reduced post-procedure medications.

The prevalence of GERD has been on the rise worldwide and can be linked to esophageal cancer, one of the fastest growing cancers globally. Some GERD patients can develop changes in the lining of their esophagus leading to a condition known as Barrett’s esophagus. Most cases of esophageal cancer result from this condition. For GERD patients, MUSE offers a potential long-term solution by restoring their esophageal anatomy with a minimally invasive tool to reduce or eliminate their symptoms.

"We are proud that the renowned Johns Hopkins Hospital, along with Dr. Khashab, have adopted the MUSE procedure to help enhance GERD patient care in the U.S.”, said Chris Rowland, CEO of Medigus. “About 20% of Americans suffer from severe GERD symptoms each year, many of whom fall within a growing treatment gap between drug therapy and invasive surgical procedures. MUSE offers a novel solution by addressing the root cause of GERD to deliver a long-term relief without the need for incisions. Therefore, we expect the use of MUSE will continue to grow in both the U.S. and abroad.”

Medigus has merged recent breakthroughs in visualization, ultrasound and surgical stapling capabilities into a single platform with MUSE. The device is fully integrated with leading microvisual, ultrasonic and stapling technology, and therefore allows a single physician or surgeon to perform fundoplication (connecting the upper part of the stomach, or fundus, to the lower esophageal sphincter). MUSE has the potential to improve GERD-related quality of life for many patients by addressing the root cause of the disorder, not just offer symptom relief, which is often in contrast to many drug therapies.